Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.47 |
| ▸ | ACHE | P22303 | 4/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7553615 | 0.92 | CCR2 (0.54) | CCR2HRH3ACHEHRH4KDM4E | |
| SCHEMBL7546613 | 0.89 | CCR2 (0.68) | CCR2HRH3ACHESIGMAR1KDM4E | |
| SCHEMBL7549627 | 0.87 | HRH3 (0.52) | CCR2HRH3ACHEKDM4E | |
| SCHEMBL7551142 | 0.85 | CCR2 (0.43) | CCR2HRH3ACHEHRH4SIGMAR1 | |
| SCHEMBL7552060 | 0.83 | HRH3 (0.47) | CCR2HRH3ACHESIGMAR1KDM4E | |
| SCHEMBL7553586 | 0.82 | CCR2 (0.64) | CCR2HRH3ACHEHRH4SIGMAR1 | |
| SCHEMBL7546720 | 0.82 | CCR2 (0.79) | CCR2ACHEHRH4MCHR1 | |
| SCHEMBL7553497 | 0.81 | HRH3 (0.47) | CCR2HRH3ACHEKDM4E | |
| SCHEMBL7550676 | 0.78 | HRH3 (0.54) | CCR2HRH3ACHESIGMAR1KDM4E | |
| SCHEMBL7546719 | 0.78 | HRH3 (0.48) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020099054-A1 | 2-phenyl benzimidazole derivatives as MCP-1 antagonists | WARNER-LAMBERT COMPANY (US) | 2002-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099054-A1 | 2-phenyl benzimidazole derivatives as MCP-1 antagonists | CCR1, CCR2, CCR8 | CCR2 2/4885HRH3 165/4885ACHE 4652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.